LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Bassendine, Margaret F.; Sheridan, David A.; Felmlee, Daniel J.; Bridge, Simon H.; Toms, Geoffrey L; Neely, R. Dermot G. (2011)
Publisher: Elsevier BV
Journal: Journal of Hepatology
Languages: English
Types: Article
Subjects: Hepatology, A300

Classified by OpenAIRE into

mesheuropmc: lipids (amino acids, peptides, and proteins)
Atherosclerosis has been described as a liver disease of the heart. The liver is the central regulatory organ of lipid pathways but since dyslipidaemias are major contributors to cardiovascular disease and type 2 diabetes rather than liver disease, research in this area has not been a major focus for hepatologists. Virus-host interaction is a continuous co-evolutionary process involving the host immune system and viral escape mechanisms. One of the strategies HCV has adopted to escape immune clearance and establish persistent infection is to make use of hepatic lipid pathways. This review aims to: update the hepatologist on lipid metabolism; review the evidence that HCV exploits hepatic lipid pathways to its advantage; discuss approaches to targeting host lipid pathways as adjunctive therapy.

Share - Bookmark

Cite this article